Effect of progestin-based contraceptives on HIV-associated vaginal immune biomarkers and microbiome in adolescent girls.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 04 07 2023
accepted: 13 06 2024
medline: 15 7 2024
pubmed: 15 7 2024
entrez: 15 7 2024
Statut: epublish

Résumé

Adolescent girls bear a disproportionate burden of both the HIV epidemic and unintended pregnancies; yet important questions remain unanswered regarding the effects of hormonal contraceptives on the vaginal immune microenvironment, which can impact HIV susceptibility in this group. Multiple studies report genital immune alterations associated with the progestin-based contraceptive Depot medroxyprogesterone acetate (DMPA) in adult women, but there is little available data in adolescents. The objective of this longitudinal cohort study was to evaluate the effects of short-term use of three progestin-based contraceptives, levonorgestrel intrauterine device (LNG-IUD), subdermal etonogestrel (ETNG), and injectable DMPA, on HIV-associated vaginal immune biomarkers and microbiome in adolescent girls. Fifty-nine sexually active, HIV-uninfected girls aged 15-19, were recruited from the Washington DC metro area and self-selected into Control (condoms only), combined oral contraceptive pills, LNG-IUD, ETNG and DMPA groups. Vaginal swabs were collected at baseline prior to contraceptive use and at 3-month follow-up visit. Vaginal secretions were tested for pro-inflammatory (IL-1α, IL-1β, TNF-α, IL-6, IL-8, MIP-3α, IP-10, RANTES, MIP-1α, MIP-1β) and anti-inflammatory/anti-HIV (Serpin-A1, Elafin, Beta-Defensin-2, SLPI) immune biomarkers using ELISA and for anti-HIV activity using TZM-bl assay. Vaginal microbiome was evaluated using 16S rRNA gene sequencing. Data were analyzed using SAS Version 9. Among the 34 participants who completed both visits, no significant changes in median biomarker concentrations, HIV inhibition and microbiome composition were observed between baseline and follow-up visits for any of the contraceptive groups. IL-8 (p<0.01), MIP-3α (0.02), Elafin (p = 0.03) and RANTES (p<0.01) differed significantly by race whereas IL-6 was significantly different by age (p = 0.03). We conclude that 3-month use of LNG-IUD, ETNG and DMPA have minimal effects on adolescent vaginal immune microenvironment, and therefore unlikely to impact HIV risk. Future studies with larger sample size and longer follow-up are recommended to continue to evaluate effects of contraceptives on the lower genital tract immunity and susceptibility to sexually transmitted infections.

Identifiants

pubmed: 39008499
doi: 10.1371/journal.pone.0306237
pii: PONE-D-23-19489
doi:

Substances chimiques

Biomarkers 0
Medroxyprogesterone Acetate C2QI4IOI2G
Levonorgestrel 5W7SIA7YZW
Desogestrel 81K9V7M3A3
etonogestrel 304GTH6RNH
Contraceptive Agents, Female 0
Progestins 0
Elafin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0306237

Informations de copyright

Copyright: © 2024 Nasr et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Mélodie A Nasr (MA)

Department of Epidemiology, George Washington University, Washington, DC, United States of America.

Annette Aldous (A)

Department of Biostatistics and Bioinformatics, George Washington University, Washington, DC, United States of America.

Jason Daniels (J)

Department of Epidemiology, George Washington University, Washington, DC, United States of America.

Christopher Joy (C)

Department of Epidemiology, George Washington University, Washington, DC, United States of America.

Eleanor Capozzi (E)

Department of Epidemiology, George Washington University, Washington, DC, United States of America.

Michelle Yang (M)

Department of Epidemiology, George Washington University, Washington, DC, United States of America.

Patricia Moriarty (P)

MedStar Washington Hospital Center, Washington, DC, United States of America.

Vanessa Emmanuel-Baker (V)

MedStar Washington Hospital Center, Washington, DC, United States of America.

Sharyn Malcolm (S)

Children's National Hospital, Washington, DC, United States of America.

Stefan J Green (SJ)

Genomics and Microbiome Core Facility, Rush University, Chicago, IL, United States of America.

Veronica Gomez-Lobo (V)

MedStar Washington Hospital Center, Washington, DC, United States of America.
Children's National Hospital, Washington, DC, United States of America.
National Institute of Child Health and Human Development, National Institutes of Health, Washington, DC, United States of America.

Mimi Ghosh (M)

Department of Epidemiology, George Washington University, Washington, DC, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH